Terms: = Lymphoma AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
121 results:
1. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
3. Determination of T-cell clonality and expression profiles of Toll-like receptors signaling pathway genes and related miRNAs in patients with mycosis fungoides.
Seçme M; Dodurga Y; Demirkan NÇ; Kaçar N; Günel NS; Açıkbaş İ
Gene; 2024 Jan; 891():147825. PubMed ID: 37748629
[TBL] [Abstract] [Full Text] [Related]
4. Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative
Nazmy MH; Abu-Baih DH; Elrehany MA; Mustafa M; Aly OM; El-Sheikh AAK; Fathy M
Front Biosci (Landmark Ed); 2023 Aug; 28(8):185. PubMed ID: 37664933
[TBL] [Abstract] [Full Text] [Related]
5. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
Salaverria I; Weigert O; Quintanilla-Martinez L
Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
[TBL] [Abstract] [Full Text] [Related]
6. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S; Travaini L; Botta F; Granata C; Motta G; Melle F; Fiori S; Tabanelli V; Vanazzi A; Ramadan S; Radice T; Raimondi S; Lo Presti G; Ferrari ME; Jereczek-Fossa BA; Tarella C; Ceci F; Pileri S; Derenzini E
Blood Adv; 2023 Feb; 7(4):630-643. PubMed ID: 36806558
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.
Lee J; Han JH; Lee CH; Park HS; Min SK; Lee H; Cho U; Yoon SE; Kim SJ; Kim WS; Cho J
Virchows Arch; 2023 May; 482(5):849-858. PubMed ID: 36656392
[TBL] [Abstract] [Full Text] [Related]
8. A kinase inhibitor screen reveals mek1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
[TBL] [Abstract] [Full Text] [Related]
9. [Rosai-Dorfman-Destombes disease with a misleading laryngeal presentation].
Fiani DJ; Émile JF; Istier L; Boutin AB; Tychyj C; Benzerdjeb N; Donzel M; Balme B; Traverse-Glehen A; Fontaine J
Ann Pathol; 2022 Nov; 42(6):475-480. PubMed ID: 36038429
[TBL] [Abstract] [Full Text] [Related]
10. Pediatric-Type Indolent B-Cell lymphomas With Overlapping Clinical, Pathologic, and Genetic Features.
Lim S; Lim KY; Koh J; Bae JM; Yun H; Lee C; Kim YA; Paik JH; Jeon YK
Am J Surg Pathol; 2022 Oct; 46(10):1397-1406. PubMed ID: 35834399
[TBL] [Abstract] [Full Text] [Related]
11. A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.
Salmeron-Villalobos J; Egan C; Borgmann V; Müller I; Gonzalez-Farre B; Ramis-Zaldivar JE; Nann D; Balagué O; López-Guerra M; Colomer D; Oschlies I; Klapper W; Glaser S; Ko YH; Bonzheim I; Siebert R; Fend F; Pittaluga S; Campo E; Salaverria I; Jaffe ES; Quintanilla-Martinez L
Blood Adv; 2022 Aug; 6(16):4661-4674. PubMed ID: 35609565
[TBL] [Abstract] [Full Text] [Related]
12. B-cell receptor signaling induces proteasomal degradation of PDCD4 via mek1/2 and mTORC1 in malignant B cells.
Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
[TBL] [Abstract] [Full Text] [Related]
13. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
[TBL] [Abstract] [Full Text] [Related]
14. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract] [Full Text] [Related]
15. Activation of mek1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell lymphoma.
Jia X; He Q; Zeng M; Chen Y; Liu Y
Anal Cell Pathol (Amst); 2021; 2021():6668947. PubMed ID: 34239803
[TBL] [Abstract] [Full Text] [Related]
16. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
17. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
18. Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?
Matutes E
Expert Rev Hematol; 2021 Apr; 14(4):355-363. PubMed ID: 33759673
[TBL] [Abstract] [Full Text] [Related]
19. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract] [Full Text] [Related]
20. From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature.
Tashakori M; Thakral B; Tang G; Khoury JD; Medeiros LJ
Ann Diagn Pathol; 2021 Jun; 52():151720. PubMed ID: 33676171
[TBL] [Abstract] [Full Text] [Related]
[Next]
